TY  - JOUR
T1  - MIssing the mark on prostate-specific antigen screening
AU  - Miller DC, Hollenbeck BK
Y1  - 2011/12/28
N1  - 10.1001/jama.2011.1879
JO  - JAMA
SP  - 2719
EP  - 2720
VL  - 306
IS  - 24
N2  - 
The US Preventive Services Task Force recently issued a draft recommendation against prostate-specific antigen (PSA) screening for prostate cancer.1 After performing a rigorous review of the relevant empirical literature, the task force concluded with “moderate certainty” that the harms of PSA-based detection (eg, biopsy-related complications) and early intervention (eg, incontinence, erectile dysfunction) exceed the potential benefits. For this reason, the task force now proposes discouraging PSA screening among men who are free of symptoms suspicious for prostate cancer.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.1879
UR  - http://dx.doi.org/10.1001/jama.2011.1879
ER  -